Neuphoria Responds To Lynx1’S Revised Indication Of Interest At A Reduced Price And Premium
I'm PortAI, I can summarize articles.
Neuphoria Therapeutics Inc responds to Lynx1's revised bid at a reduced price and premium, lower than the initial $4.75 per share. The company has received substantial competing interests and paused R&D expenditures for BNC210 in PTSD, evaluating strategic options. Neuphoria urges stockholders to vote for its nominees on the white proxy card.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments